U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C3H5O3
Molecular Weight 89.07
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge -1

SHOW SMILES / InChI
Structure of LACTATE ION, L-

SMILES

C[C@H](O)C([O-])=O

InChI

InChIKey=JVTAAEKCZFNVCJ-REOHCLBHSA-M
InChI=1S/C3H6O3/c1-2(4)3(5)6/h2,4H,1H3,(H,5,6)/p-1/t2-/m0/s1

HIDE SMILES / InChI
Lactic Acid, L- (L-lactic acid, L-lactate) is the levorotatory isomer of lactic acid, the biologically active isoform in humans. Lactic acid or lactate is produced during fermentation from pyruvate by lactate dehydrogenase. Lactate dehydrogenase is isomer-specific so that production and metabolism of D-lactate require D-LDH and L-lactate requires L-LDH. Mammalian cells only contain L-LDH so that in humans the lactate produced is almost exclusively L-lactate. Carbohydrate-fermenting bacterial species (e.g. lactobacillus spp) have by contrast both enzymes and therefore the capacity to produce both D-lactate and L-lactate. L-lactic acid is the primary agonist of hydroxycarboxylic acid receptor 1 (HCA1), which is a Gi/o-coupled G protein-coupled receptor (GPCR). Poly-L-lactic acid is an absorbable, semi-permanent, injectable implant that can be used to restore volume and stimulate collagen formation gradually. It is FDA-approved for the correction of facial fat loss associated with antiretroviral therapy-induced lipoatrophy in HIV patients. It is FDA-approved for use in immunocompetent people for the correction of nasolabial fold deficiencies and other facial wrinkles. It has been used off-label to enhance the cheeks, hands, neck, thighs, gluteal enhancement and chest wall deformities, such as pectus excavatum or thoracic deformities secondary to surgical procedures.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q9BXC0
Gene ID: 27198.0
Gene Symbol: HCAR1
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
PRISMASOL

Approved Use

PRISMASOL solution is indicated as a replacement solution in Continuous Renal Replacement Therapy (CRRT) and in case of drug poisoning when CRRT is used to remove dialyzable substances.

Launch Date

2006
PubMed

PubMed

TitleDatePubMed
High resolution 1H n.m.r. studies of vertebrate blood and plasma.
1983 Jun 1
Lactate- and isoproterenol-induced panic attacks in panic disorder patients and controls.
1988 Feb
1H NMR characterization of normal human cerebrospinal fluid and the detection of methylmalonic acid in a vitamin B12 deficient patient.
1991 Aug
Malignant ventricular tachycardia during propafenone treatment in a child with junctional automatic tachycardia: effectiveness of intravenous molar sodium lactate.
1991 May
Physiology and pathophysiology of organic acids in cerebrospinal fluid.
1993
Abnormal substrate levels that depend upon mitochondrial function in cerebrospinal fluid from Alzheimer patients.
1998
Paraquat-induced renal injury studied by 1H nuclear magnetic resonance spectroscopy of urine.
1998 Jun
Optimisation of media and cultivation conditions for L(+)(S)-lactic acid production by Lactobacillus casei NRRL B-441.
2001 Jul
Asymmetric intramolecular [2 + 2] photocycloadditions: alpha- and beta-hydroxy acids as chiral tether groups.
2002 Feb 22
1H and (13)C NMR spectroscopic analysis of human saliva.
2002 Jun
Synthesis of optically active atropisomeric anilide derivatives through diastereoselective N-allylation with a chiral Pd-pi-allyl catalyst.
2003 Dec 12
Structure of the O-polysaccharide of Proteus penneri 28 and Proteus vulgaris O31 and classification of P. penneri 26 and 28 in Proteus serogroup O31.
2003 Oct 24
Physiological and behavioral effects of naloxone and lactate in normal volunteers with relevance to the pathophysiology of panic disorder.
2007 Jan 15
Role of GPR81 in lactate-mediated reduction of adipose lipolysis.
2008 Dec 19
Overcoming extractability hurdles of a 14C labeled taxane analogue milataxel and its metabolite from xenograft mouse tumor and brain tissues.
2009 Apr 5
Examination of the biological role of the alpha(2-->6)-linked sialic acid in gangliosides binding to the myelin-associated glycoprotein (MAG).
2009 Feb 26
Lactate inhibits lipolysis in fat cells through activation of an orphan G-protein-coupled receptor, GPR81.
2009 Jan 30
Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
2009 May 1
Studies on the biodegradation of fosfomycin: growth of Rhizobium huakuii PMY1 on possible intermediates synthesised chemically.
2009 May 7
Patents

Sample Use Guides

Facial fat loss (lipoatrophy) Sculptra (Poly-L-lactic acid): Intradermal or SubQ: ~0.05-0.2 mL per individual injection depending on technique used; ~20 injections may be needed per cheek. Treatment should be individualized. Separate treatments by ≥2 weeks. Typical course involves 3-6 treatments. Supplemental injections may be needed. Do not overfill contour deficiency. For patients with severe facial fat loss, the average treatment requires ~1 vial per cheek area per treatment.
Route of Administration: Other
Name Type Language
LACTATE ION, L-
Common Name English
LACTIC ACID, ION(1-), L-
Systematic Name English
(S)-(+)-LACTATE ION
Common Name English
PROPANOIC ACID, 2-HYDROXY-, ION(1-), (2S)-
Systematic Name English
L-LACTATE ION
Common Name English
L-LACTATE
Common Name English
LACTATE, (S)-
Systematic Name English
Code System Code Type Description
CHEBI
16651
Created by admin on Sat Dec 16 09:48:31 GMT 2023 , Edited by admin on Sat Dec 16 09:48:31 GMT 2023
PRIMARY
CAS
1977-17-9
Created by admin on Sat Dec 16 09:48:31 GMT 2023 , Edited by admin on Sat Dec 16 09:48:31 GMT 2023
SUPERSEDED
CAS
4305-71-9
Created by admin on Sat Dec 16 09:48:31 GMT 2023 , Edited by admin on Sat Dec 16 09:48:31 GMT 2023
SUPERSEDED
EPA CompTox
DTXSID801018949
Created by admin on Sat Dec 16 09:48:31 GMT 2023 , Edited by admin on Sat Dec 16 09:48:31 GMT 2023
PRIMARY
FDA UNII
435SSH7H89
Created by admin on Sat Dec 16 09:48:31 GMT 2023 , Edited by admin on Sat Dec 16 09:48:31 GMT 2023
PRIMARY
RXCUI
1427172
Created by admin on Sat Dec 16 09:48:31 GMT 2023 , Edited by admin on Sat Dec 16 09:48:31 GMT 2023
PRIMARY
PUBCHEM
5460161
Created by admin on Sat Dec 16 09:48:31 GMT 2023 , Edited by admin on Sat Dec 16 09:48:31 GMT 2023
PRIMARY
CAS
72-08-2
Created by admin on Sat Dec 16 09:48:31 GMT 2023 , Edited by admin on Sat Dec 16 09:48:31 GMT 2023
PRIMARY
CAS
148182-33-6
Created by admin on Sat Dec 16 09:48:31 GMT 2023 , Edited by admin on Sat Dec 16 09:48:31 GMT 2023
SUPERSEDED